Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN ADES

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1972796167
CMS profile
960636
Location
BURLINGTON, VT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$120.04

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $120.04 4

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Astellas Pharma US Inc $99.99 1
PFIZER INC. $20.05 3

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN ADES

NPI 1972796167 · CMS profile ID 960636

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BURLINGTON, VT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972796167?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN ADES, NPI 1972796167, CMS profile ID 960636. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972796167?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). STEVEN ADES, NPI 1972796167, CMS profile ID 960636. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972796167?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
STEVEN ADES, NPI 1972796167, CMS profile ID 960636, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1972796167?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $120.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $99.9910/17/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655436115 CMS
PFIZER INC. $8.1205/21/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671976117 CMS
PFIZER INC. $1.2305/21/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672364801 CMS
PFIZER INC. $10.7005/21/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672396855 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $120.04 4
PY2025 $25.70 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $90,833.66 5
PY2024 Principal investigator $189,558.75 28
PY2023 Principal investigator $129,579.24 18
PY2022 Principal investigator $139,160.39 28
PY2021 Principal investigator $82,147.48 26
PY2020 Recipient $4,600.00 2
PY2020 Principal investigator $258,725.27 56
PY2019 Recipient $3,069.83 34
PY2019 Principal investigator $223,598.60 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,739.80 12/31/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer No dispute reported 06/30/2026 736736543
Principal investigator 1 EMD Serono, Inc. $68.00 12/31/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749587955
Principal investigator 1 EMD Serono, Inc. $2,340.00 12/23/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749612047
Principal investigator 1 EMD Serono, Inc. $3,900.00 12/23/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749616101
Principal investigator 1 EMD Serono, Inc. $5,469.00 12/23/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749616637
Recipient PFIZER INC. $1,400.00 12/04/2020 Covered Recipient Physician CRIZOTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742857471
Principal investigator 1 EMD Serono, Inc. $68.00 11/30/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749587989
Principal investigator 1 EMD Serono, Inc. $764.00 11/02/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749601745
Principal investigator 1 EMD Serono, Inc. $764.00 11/02/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749601749
Principal investigator 1 EMD Serono, Inc. $764.00 11/02/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749601753
Principal investigator 1 EMD Serono, Inc. $764.00 11/02/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749601757
Principal investigator 1 EMD Serono, Inc. $764.00 11/02/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749601761
Principal investigator 1 EMD Serono, Inc. $68.00 10/30/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749588035
Principal investigator 1 EMD Serono, Inc. $68.00 09/30/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749587851
Principal investigator 1 PFIZER INC. $1,500.00 09/17/2020 Covered Recipient Teaching Hospital
UNIVERSITY OF VERMONT MEDICAL CENTER
PHASE 1 SAFETY PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF02341066 A CMETHGFR SELECTIVE TYROSINE KINASE INHIBITOR ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER No dispute reported 06/30/2026 742928857
Principal investigator 1 EMD Serono, Inc. $361.70 09/03/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749607923
Principal investigator 1 EMD Serono, Inc. $68,053.42 09/03/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749618077
Principal investigator 1 EMD Serono, Inc. $68.00 08/31/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749587887
Principal investigator 1 PFIZER INC. $1,500.00 08/13/2020 Covered Recipient Teaching Hospital
UNIVERSITY OF VERMONT MEDICAL CENTER
PHASE 1 SAFETY PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF02341066 A CMETHGFR SELECTIVE TYROSINE KINASE INHIBITOR ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER No dispute reported 06/30/2026 742928861
Principal investigator 1 EMD Serono, Inc. $68.00 07/31/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749587908
Recipient PFIZER INC. $3,200.00 07/15/2020 Covered Recipient Physician CRIZOTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742857465
Principal investigator 1 EMD Serono, Inc. $68.00 06/30/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749587811
Principal investigator 1 EMD Serono, Inc. $14,186.98 06/23/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749618073
Principal investigator 1 EMD Serono, Inc. $5.60 06/01/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603701
Principal investigator 1 EMD Serono, Inc. $3,900.00 06/01/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749616097
Principal investigator 1 EMD Serono, Inc. $68.00 05/29/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749587793
Principal investigator 1 EMD Serono, Inc. $1,500.00 05/06/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749607817
Principal investigator 1 EMD Serono, Inc. $764.00 05/04/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749601733
Principal investigator 1 EMD Serono, Inc. $764.00 05/04/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749601737
Principal investigator 1 EMD Serono, Inc. $764.00 05/04/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749601739
Principal investigator 1 EMD Serono, Inc. $3,535.00 05/04/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749615891
Principal investigator 1 EMD Serono, Inc. $4,313.00 05/04/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749616233
Principal investigator 1 AstraZeneca Pharmaceuticals LP $31,340.41 04/30/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer No dispute reported 06/30/2026 736745331
Principal investigator 1 EMD Serono, Inc. $68.00 04/30/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749587771
Principal investigator 1 EMD Serono, Inc. $1,194.00 04/14/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749605803
Principal investigator 1 EMD Serono, Inc. $1,194.00 04/14/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749605805
Principal investigator 1 EMD Serono, Inc. $1,194.00 04/14/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749605809
Principal investigator 1 EMD Serono, Inc. $2,000.00 04/09/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749610839
Principal investigator 1 EMD Serono, Inc. $3,535.00 04/01/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749615889
Principal investigator 1 EMD Serono, Inc. $68.00 03/31/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749587759
Principal investigator 1 EMD Serono, Inc. $2,340.00 03/09/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749612033
Principal investigator 1 EMD Serono, Inc. $3,250.00 03/09/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749615563
Principal investigator 1 EMD Serono, Inc. $3,900.00 03/09/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749616095
Principal investigator 1 EMD Serono, Inc. $10,400.00 03/09/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749617503
Principal investigator 1 EMD Serono, Inc. $68.00 02/28/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749587753
Principal investigator 1 EMD Serono, Inc. $121.83 02/07/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749591395
Principal investigator 1 EMD Serono, Inc. $211.00 02/07/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749592307
Principal investigator 1 EMD Serono, Inc. $410.00 02/07/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749595900
Principal investigator 1 EMD Serono, Inc. $430.01 02/07/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749596253
Principal investigator 1 EMD Serono, Inc. $661.34 02/07/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749600173
Principal investigator 1 EMD Serono, Inc. $2,130.00 02/07/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749611473
Principal investigator 1 EMD Serono, Inc. $4,053.20 02/07/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749616175
Principal investigator 1 EMD Serono, Inc. $5,062.50 02/07/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749616529
Principal investigator 1 EMD Serono, Inc. $5,131.14 02/07/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749616543
Principal investigator 1 EMD Serono, Inc. $6,551.94 02/07/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749616985
Principal investigator 1 Eli Lilly and Company $710.40 01/28/2020 Covered Recipient Teaching Hospital
UNIVERSITY OF VERMONT MEDICAL CENTER
A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CANCER No dispute reported 06/30/2026 728730207
Principal investigator 1 EMD Serono, Inc. $1,500.00 01/20/2020 Covered Recipient Teaching Hospital
University Of Vermont Medical Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749607789
Principal investigator 1 Eli Lilly and Company $51,240.00 01/17/2020 Covered Recipient Teaching Hospital
UNIVERSITY OF VERMONT MEDICAL CENTER
A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CANCER No dispute reported 06/30/2026 728729077